Forte Biosciences concluded its 30-day news cycle dominated by argenx's $2.2 billion acquisition announcement at $77 per share, representing a 40 percent premium to pre-deal valuations. The transaction, disclosed July 27, generated overwhelmingly bullish sentiment across coverage, with ten articles averaging a 0.75/1.0 grade score and predominantly positive positioning from institutional investors including Fred Alger Management. The deal's strategic rationale centers on FB102, a first-in-class anti-CD122 antibody in Phase 1b trials targeting vitiligo and other immunology indications. This acquisition signals argenx's aggressive portfolio expansion within dermatology and immunology, consolidating intellectual property while deploying capital decisively. The transaction premium reflects management confidence in FB102's clinical potential and market opportunity. Sector context shows active M&A momentum in clinical-stage biotech, with related equities ARGX, GOSS, OMER, ENTX, and SION demonstrating parallel consolidation trends. Forward implications suggest accelerated regulatory pathways under argenx's operational framework, potentially shortening timelines to clinical inflection points. FBRX shareholders captured premium value exit pricing, fundamentally altering the company's standalone trajectory.